INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Why A Strong CMC Roadmap Is Essential For Cell Therapy Program Success

  A structured regulatory roadmap and early management of manufacturing, materials, and assay testing help reduce risk and prevent costly delays in cell therapy development.

• Late-Phase Process Development Capabilities Are Stronger Than Ever

  Late-phase cell therapy programs require process control, automation, and characterization to improve consistency, reduce regulatory risk, and enable commercial-scale manufacturing.

• How To Build A Cell Therapy CMC Roadmap

  A structured, phase-appropriate regulatory roadmap helps cell therapy developers reduce risk, streamline manufacturing and testing, and avoid costly clinical delays.

• Reducing The Time And Cost Of Robust Analytical Method Development

  Design-of-experiment methodology accelerates cell therapy assay development, reducing costs and timelines while improving assay robustness, regulatory readiness, and data-driven decision-making.

• A Rapid Approach To Streamlined CART Therapies And Reduced Cost

  Advanced engineered vectors streamline cell therapy manufacturing, cutting operational steps by 40% and reducing material costs while maintaining T-cell purity and potency.

• FUJIFILM Biotechnologies Capabilities Update July 2026: Gene Therapy

  From process development to GMP manufacturing, our teams operate as one connected system to support your cell or gene therapy through every milestone.

• Why Clinical Operations Is The Bridge To Patient Access

  Autologous cell therapies depend on time-critical supply chains. Automated processing, rapid testing, and centralized data help streamline vein-to-vein delivery and expand access.

• Integrated Vs. Modular CDMO Strategy For Advanced Therapies

  Fragmented manufacturing increases tech transfer risk, delays timelines, and causes data loss. A unified framework preserves continuity and accelerates advanced therapy delivery.

• Scaling MSC Therapies To GMP: The Variability Challenge

  Scaling stem cell therapies hinges on managing biological variability. Learn how automated 3D processing, defined media, and robust analytics drive predictable development.

• What Sponsors Value Most In CRO Partnerships

  If your organization is uncertain about what truly separates strong research partnerships from disappointing ones, these data-driven findings can help you improve how you select, evaluate, and manage CRO partnerships.